PNI as a Potential Add-On Biomarker to Improve the IMDC Intermediate Prognostic Score

Author:

Bayoğlu İbrahim Vedat1,Hüseynov Javid1,Topal Alper2ORCID,Sever Nadiye1,Majidova Nargiz1,Çelebi Abdussamet1,Yaşar Alper1ORCID,Arıkan Rukiye1,Işık Selver1,Hacıoğlu Muhammet Bekir2ORCID,Ercelep Özlem1,Sarı Murat1ORCID,Erdoğan Bülent2,Hacıbekiroğlu İlhan3,Topaloğlu Sernaz2,Köstek Osman1,Çiçin İrfan2ORCID

Affiliation:

1. Department of Medical Oncology, School of Medicine, Marmara University, 34899 Istanbul, Turkey

2. Department of Medical Oncology, School of Medicine, Trakya University, 22000 Edirne, Turkey

3. Department of Medical Oncology, School of Medicine, Sakarya University, 54290 Sakarya, Turkey

Abstract

Introduction: This study aimed to assess the role of the adjusted PNI-IMDC risk scoring system in stratifying the intermediate group of metastatic RCC patients who received TKIS in the first-line setting. Methods: A total of 185 patients were included. The adjusted PNI and IMDC model was used to divide the intermediate group into two groups: intermediate PNI-high and intermediate PNI-low groups. The statistical data were analyzed using Kaplan–Meier and Cox regression analysis. Results: The results showed that the adjusted PNI-IMDC risk score, classic IMDC, and PNI had similar prognostic values. Adjusted PNI-IMDC risk score might be used for a more homogeneous differentiation of the classic intermediate group. On the other hand, multivariate analysis revealed that the presence of nephrectomy, adjusted favorable/intermediate (PNI-high) group, ECOG performance score, and presence of bone metastasis were independent predictors of OS. Conclusions: Pre-treatment PNI, as a valuable and potential add-on biomarker to the adjusted PNI-IMDC classification model, can be helpful for establishing an improved prognostic model for intermediate group mRCC patients treated with first-line TKISs. Further validation studies are needed to clarify these findings.

Publisher

MDPI AG

Subject

General Medicine

Reference29 articles.

1. Cancer Statistics, 2017;Siegel;CA Cancer J. Clin.,2017

2. Histological subtype is an independent predictor of outcome for patients with renal cell carcinoma;Leibovich;J. Urol.,2010

3. Howlader, N.N.A., Krapcho, M., Miller, D., Brest, A., Yu, M., Ruhl, J., Tatalovich, Z., Mariotto, A., Lewis, D.R., and Chen, H.S. (2023, August 30). SEER Cancer Statistics, Review, Based on November 2016 SEER Data Submission, Posted to the SEER Web Site aNCI, Bethesda MAahscgc, Available online: https://seer.cancer.gov/csr/1975_2014/.

4. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma;Motzer;J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol.,2002

5. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: Results from a large, multicenter study;Heng;J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol.,2009

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3